Cathepsin B and H activities and cystatin C concentrations in cerebrospinal fluid from patients with leptomeningeal metastasis

Clinica Chimica Acta

Volumn 329, Issue 1-2, 2003, Pages 53-60

  Nagai, Atsushi ^a   Terashima, Masaharu ^a   Harada, Takayuki ^a   Shimode, Koichi ^a   Takeuchi, Hiromi ^a   Murakawa, Yohko ^a   Nagasaki, Makoto ^a   Nakano, Akinobu ^a   Kobayashi, Shotai ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

Cathepsin B; Cathepsin H; Cerebrospinal fluid; Cystatin C; Leptomeningeal metastasis

Indexed keywords

CATHEPSIN B; CATHEPSIN H; CYSTATIN C;

ADOLESCENT; ADULT; ARTICLE; AUTOPSY; CANCER PATIENT; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CEREBROSPINAL FLUID LEVEL; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKEMIA; LYMPHOMA; MALE; MENINGEAL METASTASIS; MOLECULAR BIOLOGY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; SCHOOL CHILD; SOLID TUMOR; TUMOR CELL; WESTERN BLOTTING;

EID: 0037364246     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(03)00023-8     Document Type: Article

References (25)

1. Balm M., Hammack J. Leptomeningeal carcinomatosis. Presenting features and prognostic factors. Arch. Neurol. 53:1996;626-632.
2. Recht L.D. Neurologic complications of systemic lymphoma. Neurol. Clin. 9:1991;1001-1015.
3. Walker R.W. Neurologic complications of leukemia. Neurol. Clin. 9:1991;989-999.
4. Aznavoorian S., Murphy A.N., Stetler-Stevenson W.G., Liotta L.A. Molecular aspects of tumor cell invasion and metastasis. Cancer. 71:1993;1368-1383.
5. Kos J., Smid A., Krasovec M., Svetic B., Lenarcic B., Vrhovec I.et al. Lysosomal proteases cathepsins D, B, H, L and their inhibitors stefins A and B in head and neck cancer. Biol. Chem. Hoppe-Seyler. 376:1995;401-405.
6. Budihna M., Strojan P., Smid L., Skrk J., Vrhovec I., Zupevc A.et al. Prognostic value of cathepsins B, H, L, D and their endogenous inhibitors stefins A and B in head and neck carcinoma. Biol. Chem. Hoppe-Seyler. 377:1996;385-390.
7. Lah T.T., Kos J. Cysteine proteinases in cancer progression and their clinical relevance for prognosis. Biol. Chem. 379:1998;125-130.
8. Nagai A., Murakawa Y., Terashima M., Shimode K., Takeuchi H., Kobayashi S. Cystatin C and cathepsin B in CSF fluid from patients with inflammatory neurological diseases. Neurology. 55:2000;1828-1832.
9. Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C.et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 13:1983;227-231.
10. Barrett A.J., Kirschke H. Cathepsin B, cathepsin H, and cathepsin L. Methods Enzymol. 80:1981;535-561.
11. Shimode K., Fujihara S., Nakamura M., Kobayashi S., Tsunematsu T. Diagnosis of cerebral amyloid angiopathy by enzyme-linked immunosorbent assay of cystatin C in cerebrospinal fluid. Stroke. 22:1991;860-866.
12. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. U. S. A. 76:1979;4350-4354.
13. Keppler D., Sloane B.F. Cathepsin B: multiple enzyme forms from a single gene and their relation to cancer. Enzyme Protein. 49:1996;94-105.
14. Buck M.R., Karustis D.G., Day N.A., Honn K.V., Sloane B.F. Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues. Biochem. J. 282:1992;273-278.
15. Yan S., Sameni M., Sloane B.F. Cathepsin B and human tumor progression. Biol. Chem. 379:1998;113-123.
16. Burnett D., Crocker J., Vaughan A.T. Synthesis of cathepsin B by cells derived from the HL60 promyelocytic leukaemia cell line. J. Cell. Physiol. 115:1983;249-254.
17. Kobayashi H., Ohi H., Sugimura M., Shinohara H., Fujii T., Terao T. Inhibition of in vitro ovarian cancer cell invasion by modulation of urokinase-type plasminogen activator and cathepsin B. Cancer Res. 52:1992;3610-3614.
18. Corticchiato O., Cajot J.F., Abrahamson M., Chan S.J., Keppler D., Sordat B. Cystatin C and cathepsin B in human colon carcinoma: expression by cell lines and matrix degradation. Int. J. Cancer. 52:1992;645-652.
19. Sexton P.S., Cox J.L. Inhibition of motility and invasion of B16 melanoma by the overexpression of cystatin C. Melanoma Res. 7:1997;97-101.
20. Coulibaly S., Schwihla H., Abrahamson M., Albini A., Cerni C., Clark J.L.et al. Modulation of invasive properties of murine squamous carcinoma cells by heterologous expression of cathepsin B and cystatin C. Int. J. Cancer. 83:1999;526-531.
21. Rozhin J., Gomez A.P., Ziegler G.H., Nelson K.K., Chang Y.S., Fong D.et al. Cathepsin B to cysteine proteinase inhibitor balance in metastatic cell subpopulations isolated from murine tumors. Cancer Res. 50:1990;6278-6284.
22. Olafsson I., Gudmundsson G., Abrahamson M., Jensson O., Grubb A. The amino terminal portion of cerebrospinal fluid cystatin C in hereditary cystatin C amyloid angiopathy is not truncated: direct sequence analysis from agarose gel electropherograms. Scand. J. Clin. Lab. Invest. 50:1990;85-93.
23. Katunuma N., Kominami E. Distribution and localization of lysosomal cysteine proteinases and cystatins. Turk V. Cysteine proteinases and their inhibitors. 1986;219-227 Gruyter Wd & Co. New York.
24. Freilich R.J., Krol G., DeAngelis L.M. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann. Neurol. 38:1995;51-57.
25. Gleissner B., Siehl J., Korfel A., Reinhardt R., Thiel E. CSF evaluation in primary CNS lymphoma patients by PCR of the CDR III IgH genes. Neurology. 58:2002;390-396.